Hengrui Pharma's Innovative Drug Hetrombopag Olamine Tablets Gain Additional Indication

Stock News03-13 17:46

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced receiving approval from the National Medical Products Administration for an additional indication of its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. The newly approved indication authorizes the drug's use in combination with immunosuppressive therapy for patients aged 15 years and above with newly-diagnosed severe aplastic anemia (SAA). Hetrombopag Olamine Tablets were originally approved for marketing in 2021 with two indications: first, for adult patients with chronic primary immune thrombocytopenia (ITP) who had insufficient response to previous treatments such as corticosteroids or immunoglobulins; and second, for adult patients with severe aplastic anemia (SAA) who showed poor efficacy following immunosuppressive therapy (IST).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160806408?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160806408","market":"other","top_or_hot":-1,"title":"Hengrui Pharma's Innovative Drug Hetrombopag Olamine Tablets Gain Additional Indication","media":"Stock News","content":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced receiving approval from the National Medical Products Administration for an additional indication of its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. The newly approved indication authorizes the drug's use in combination with immunosuppressive therapy for patients aged 15 years and above with newly-diagnosed severe aplastic anemia (SAA). Hetrombopag Olamine Tablets were originally approved for marketing in 2021 with two indications: first, for adult patients with chronic primary immune thrombocytopenia (ITP) who had insufficient response to previous treatments such as corticosteroids or immunoglobulins; and second, for adult patients with severe aplastic anemia (SAA) who showed poor efficacy following immunosuppressive therapy (IST).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharma's Innovative Drug Hetrombopag Olamine Tablets Gain Additional Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharma's Innovative Drug Hetrombopag Olamine Tablets Gain Additional Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-13 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced receiving approval from the National Medical Products Administration for an additional indication of its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. The newly approved indication authorizes the drug's use in combination with immunosuppressive therapy for patients aged 15 years and above with newly-diagnosed severe aplastic anemia (SAA). Hetrombopag Olamine Tablets were originally approved for marketing in 2021 with two indications: first, for adult patients with chronic primary immune thrombocytopenia (ITP) who had insufficient response to previous treatments such as corticosteroids or immunoglobulins; and second, for adult patients with severe aplastic anemia (SAA) who showed poor efficacy following immunosuppressive therapy (IST).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2495084118.USD","symbol_name":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","start_time":0,"source_url":"","article_id":"1160806408","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160806408","pubTimestamp":1773395182,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced receiving approval from the National Medical Products Administration for an additional indication of its self-developed Class 1...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","600276":"恒瑞医药","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1191":"制药","BK1161":"生物科技","06978":"永泰生物-B","BK0060":"抗癌","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01276":"恒瑞医药","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0196":"行业龙头","BK1574":"生物医药B类股","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK0239":"医药制造","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK0183":"MSCI概念","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0188":"融资融券","BK0012":"证金概念","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK0028":"国家队"},"translate_title":"恒瑞医药创新药海曲泊帕乙醇胺片再获适应症","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"600276":1,"01276":1,"06978":1},"content_text":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced receiving approval from the National Medical Products Administration for an additional indication of its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. The newly approved indication authorizes the drug's use in combination with immunosuppressive therapy for patients aged 15 years and above with newly-diagnosed severe aplastic anemia (SAA). Hetrombopag Olamine Tablets were originally approved for marketing in 2021 with two indications: first, for adult patients with chronic primary immune thrombocytopenia (ITP) who had insufficient response to previous treatments such as corticosteroids or immunoglobulins; and second, for adult patients with severe aplastic anemia (SAA) who showed poor efficacy following immunosuppressive therapy (IST).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160806408","isCrawlerRequest":true}